Abstract: Methods of diagnosing and treating autism spectrum disorders are provided.

Abstract: An object of the present invention to provide therapeutic compositions and methods for the prevention and/or treatment of airway obstructive disorders that involve bronchial hyper-responsiveness (BHR), asthma, horse asthma, airway remodeling that potentiate BHR, and any other airway obstructive disorders that involve bronchial smooth muscle (BSM) constriction or possibly other airway smooth muscle (ASM) constriction in a subject in need thereof. Compositions and methods for targeting HCN channels in airway smooth muscle to treat and/or prevent asthma and asthma-like conditions are disclosed. The compositions and methods include administering a therapeutically effective amount of HCN channel blocker, preferably ivabradine hydrochloride, to a subject in need thereof.

Abstract: A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 ?g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.

Abstract: Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.

Abstract: This invention discloses uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products. This invention provides uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug estradiol, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that estradiol has a new use as an anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma medication, thus achieving a new purpose for an old drug.

Abstract: The present invention generally relates to methods and compositions for the treatment of overweight or obese individuals. In particular, the invention relates to reducing adiposity of an overweight or obese individual. The present invention provides a method for reducing adiposity or treating obesity in an individual, the method comprising inhibiting TCPTP and/or PTP1B in the hypothalamus of the individual, thereby reducing adiposity or treating obesity in the individual.

Abstract: The present disclosure provides compositions and methods of modulating abhydrolase domain-containing protein-2 (ABHD2). The present disclosure provides methods of identifying agents that modulate ABHD2 activity.

Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

Abstract: The present invention provides a food that is effective for improving the intestinal environment by promoting proliferation of intestinal lactic acid bacteria and the like. The present invention provides a food that is effective for improving the intestinal environment, wherein the food includes (1) ?-polyglutamic acid or a composition containing ?-polyglutamic acid, and (2) oligosaccharide or a composition containing oligosaccharide.

Abstract: The present invention relates to methods of treating cancer in a human subject in need thereof. In particular, the present invention relates to treating a cancer by administering a recombinant virus which expresses one or more biotherapeutic agents in a subject, and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent. The invention further relates to method for treating cancer by administering a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent and a caspase inhibitor, and, optionally, also administering a recombinant virus expressing one or more biotherapeutic agents in the subject. The invention also relates to a method for treating cancer by administering purified interferon gamma to a subject and administering to the subject a nucleotide analogue or nucleotide precursor analogue chemotherapeutic agent.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: Compositions and methods for treating cancers are provided which comprise administering a combination of antineoplastic agents, wherein the combination comprises protein kinase inhibitor, anthracycline, nucleoside analog, apoptosis-inducing molecular therapeutic or alkylating agent chemotherapeutics and one or more nucleic acid molecules capable of down-regulating expression of at least one splice variant of the IG20 gene, and wherein not all splice variants of the IG20 gene are down-regulated. Preferably, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, shRNA and antisense oligonucleotides which comprise a nucleic acid sequence complementary to a nucleic acid sequence of exon 13L of the MADD splice variant or to an mRNA transcript of exon 13L of the MADD splice variant.

Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

Abstract: The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.

Abstract: A topical composition can be used to treat or inhibit onset of fibrillar collagenous growths, including but not limited to keloids. The composition includes elemental iodine carried in a non-migratory vehicle. Application of the composition can result in a significant reduction in the size of such a growth or, if applied to an area of skin susceptible to such a growth, inhibit the onset thereof.

Abstract: Methods to reduce the inflammatory response critical in the pathogenesis of asthma and asthma exacerbations via the introduction of autologous Pla2g5-deficient suppressive macrophages into the airways of patients with asthma.

Abstract: The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.

Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.

Abstract: The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34+ cells and CD3+ cells. In certain embodiments, the compositions include CD34+ cells and facilitating cells. The methods are useful for treating blood cell disorders and other disorders that can be ameliorated by providing donor hematopoietic cells.

Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Abstract: Provided herein are expanded allogeneic adipose tissue-derived stromal stem cells for use in treating complex perianal fistulas in Crohn's Disease.

Abstract: A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on he severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft.

Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Abstract: The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.

Abstract: A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach.

Abstract: Provided are gut microbes or cultures having anti-obesity efficacy and a pharmaceutical composition containing them. The gut microbes or cultures have anti-obesity efficacy by lowering fatty acid concentration of the gut fluid contents in a mammalian gastrointestinal tract for the prevention and treatment of obesity and obesity related diseases. This invention demonstrated that said gut microbes having anti-obesity efficacy by lowering fatty acid concentration of the gut fluid contents in the gastrointestinal tract of mammals have the anti-obesity efficacy as much as that of the representative anti-obesity drug, orlistat, without any side effects in animal experiments and clinical trials. Therefore, the gut microbes h can be used to develop universal anti-obesity drugs for obese patients, contributing greatly to the health of mankind.

Abstract: Lactobacillus plantarum TCI378 is provided. The Lactobacillus plantarum TCI378 was deposited at German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen and Zellkulturen, DSMZ) under the accession number DSM 32451. A method for losing fat and/or improving gastrointestinal functions is also provided. The method comprises administering to a subject in need an effective amount of a composition, wherein the composition comprises Lactobacillus plantarum TCI378 and/or its metabolites.

Abstract: An anti-inflammatory composition of Candida albicans which comprises heat-killed Candida albicans in combination with a neuroprotective supplement. The composition provides a method of stimulating a host immune response capable of reducing a total Candida albicans yeast load below the threshold necessary for the host to keep the Candida albicans yeast and related yeast species in a commensal, non-invasive state. This effect inhibits or prevents chronic inflammation related to invasive Candida genus and allows the composition to be useful for the prevention, prophylaxis, and/or treatment of chronic inflammatory conditions, as well as diseases and disorders of the central nervous system resulting from high L-glutamate levels due to Candida albicans in the gastrointestinal system.

Abstract: The present disclosure relates to methods of administering a composition to a patient, particularly in the form of a dietary supplement, which addresses immune system deficiencies and promotes healthy immune system functioning. The present disclosure also related to compositions and methods for improving or boosting immune system functioning. The present disclosure further provides novel compositions for balancing immune response in human subjects.

Abstract: Provided are a method of efficiently producing a ginseng leaf extract including rare ginsenosides Rg6, Rk3, and Rh4 in increased amounts, and use of a ginseng leaf extract produced by the method.

Abstract: The invention relates to a synergistic composition comprising a dry extract of plant of genus Galeopsis and a compound promoting autophagy selected from biotin and R-N1-spermidine or a salt thereof, wherein R is hydrogen or methyl and mixtures thereof. The synergistic compositions according to the invention may be in the form of a topical formulation or oral formulation and is useful as a promoter of autophagy especially in cells of human scalp hair follicles and in promoting hair growth and/or in the treatment of hair thinning or hair loss.

Abstract: The present invention relates to a pharmaceutical composition containing an avocado oil fraction as an active ingredient for prevention or treatment of hearing loss. Specifically, the avocado oil fraction according to the present invention, especially, an isopropanol fraction of avocado oil significantly increases the number of hair cells reduced by neomycin in zebrafish models, so the isopropanol fraction of avocado oil can be favorably used in the treatment of hearing loss.

Abstract: This document provides dietary supplement compositions. For example, dietary supplement compositions having an acetylcholinesterase inhibitor (e.g., huperzine A), a Bacopa monnieri extract, acetyl-L-carnitine or acetyl CoA, and a curcuminoid (e.g., curcumin) are provided.

Abstract: The present invention relates to an antithrombotic composition including Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume as active ingredients, and preferably includes an extract obtained by mixing Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume in a weight ratio of 1:2-2:1 and extracting the mixture. The composition of the present invention is highly effective in antithrombotic effects, identified as a platelet aggregation inhibitory effect, a thrombosis inhibitory effect, a thrombosis-delaying effect, and the like, and thus can be used as an effective herbal-medicine-based agent for preventing or treating thrombosis, an antithrombotic health food, and the like.

Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.

Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

Abstract: The present invention relates to a method and compositions for the treatment of age-related macular degeneration (AMD), in particular dry-AMD, specifically geographic atrophy (GA) or advanced dry-AMD. Specifically, the invention relates to an inner-blood-retinal-barrier (iBRB) or blood-brain-barrier (BBB) tight junction protein and/or a circadian clock protein for use in the prevention and/or treatment of age-related macular degeneration.

Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.

Abstract: This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.

Abstract: Methods and kits for mitigating a toxic effect of at least one of vesicants and caustic gases in a subject in need thereof are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the toxic effect of the vesicant or caustic gas.

Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15R? or derivatives thereof; and uses thereof.

Abstract: The present disclosure relates to a pharmaceutical composition, which comprises an IL-15 protein complex and a citrate buffer solution. In addition, the pharmaceutical composition may also comprise a sugar and a non-ionic surfactant. The pharmaceutical composition in the present disclosure demonstrates a high degree of stability even after being stored at 2-8° C. for several months.

Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing bifunctional fusion polymers or nanoparticles. These fusion polymers and nanoparticles contain two or more domains: (i) sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous lesions and (ii) domains that bind to pharmaceutical agents. The drug-binding functionality of these fusion polymers and nanoparticles is based on high-affinity, non-covalent interactions.

Abstract: The invention provides a blood substitute product comprising haemoglobin and a self-assembled microparticle having an acid having two or more acid groups and an organic base in a solvent. The particle is of micron scale. The microparticle may be obtained by contacting a bis-acid and organic base in a hydrophilic solvent, wherein the acid is insoluble or sparingly soluble in the hydrophilic solvent and the organic base is soluble in a hydrophilic solvent.

Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

Abstract: Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to one or more target nucleic acid sequences in a retrovirus genome.

Abstract: The present invention is related to arginine deiminase encapsulated into erythrocytes for use in therapy. It is in particular related to the use thereof in treating arginase-1 deficiency. Also, it relates to novel pharmaceutical compositions comprising arginine deiminase from M. arginini encapsulated into erythrocytes and the use thereof in treating diseases that may benefit from arginine depletion, such as arginine dependent cancers, in particular arginine-auxotrophic cancers, and arginase-1 deficiency.